By Sal Daher, CFA The miracle of the mRNA COVID vaccines, brought to us by two startups, leaves no doubt as to the promise of biotech. While experts expected the vaccines to take years, these startups designed theirs in days and were saving millions in a matter of months. The icing on the cake is …
By Sal Daher, CFA Early-stage biotech investing has been the preserve of deep-pocketed investors where angels have feared to tread. The reasons include that it takes a long time to train life scientists, that biology is hard, that life sciences need specialized laboratories with expensive equipment, and that biotechnologies have long and costly product cycles. …
How Angel Investing in Biotech Differs from Investing in Software Read More »
